26.02.2014 | Elisa Borghi; Solange Romagnoli; Beth Burgwyn Fuchs; Daniela Cirasola; Federica Perdoni; Delfina Tosi; Paola Braidot ..., Future Microbiology, 2014

ABSTRACT:  Aim: The aim of our study was to investigate whether biofilm production by Candida albicans clinical isolates could be a hallmark of virulence in vivo. Materials & methods: Twenty clinical isolates of C. albicans were examined via histological studies on larvae infected with ...

mehr

26.02.2014 | Carlos Tiago Alves; Isabel CFR Ferreira; Lillian Barros; Sónia Silva; Joana Azeredo; Mariana Henriques, Future Microbiology, 2014

ABSTRACT:  Aim: To evaluate the antifungal effect of gallic acid, catechin, luteolin and quercetin, phenolic compounds identified from flowers of North Eastern Portugal, against Candida planktonic and biofilm cells. Materials & methods: The MICs were determined in Candida planktonic cells and ...

mehr

24.02.2014 | Felicia Stefania Falvella; Stefania Cheli; Filippo de Braud; Emilio Clementi; Filippo Pietrantonio, Personalized Medicine, 2014

Reduced activity of DPD leads to severe toxicity in cancer patients receiving standard doses of fluoropyrimidines, particularly in the case of combination regimens. We describe a 38-year-old man with a resectable metastasis from hereditary-nonpolyposis colorectal cancer, with indication of ...

mehr

17.02.2014 | Pedro Dorado; Eva M Peñas-LLedo; Adrián LLerena, Pharmacogenomics, 2014

Pharmacogenomics , February 2014, Vol. 15, No. 3, Pages 261-264.

mehr

17.02.2014 | Pharmacogenomics, 2014

Pharmacogenomics , February 2014, Vol. 15, No. 3, Pages 257-260.

mehr

17.02.2014 | Hark Kyun Kim; Jeffrey E Green, Pharmacogenomics, 2014

Gastric cancer is the second most common cause of cancer death worldwide. Recent development of targeted agents provides clinicians with additional systemic treatment options to conventional cytotoxic agents. Predictive markers are undoubtedly important for guiding the appropriate use of ...

mehr

17.02.2014 | Amanda M Munson; Arthur F Harralson; Margaret M Plack; Tracey J Nickola, Pharmacogenomics, 2014

Background: Pharmacogenomics (PGx) plays a critical role in personalized medicine; however, most healthcare practitioners lack the training and confidence in PGx required to fully utilize its potential. Although continuing education and inclusion of PGx into the professional curricula will ...

mehr

17.02.2014 | Padmalatha S Rai; Ganesh C Pai; Jose F Alvares; Ravishankara Bellampalli; Puthiya M Gopinath; Kapaettu S ..., Pharmacogenomics, 2014

Aim:MTHFR mediates the one carbon metabolism pathway. Two common genetic variants, C677T and A1298C, of MTHFR are associated with number of human diseases, including cancer, as well as being involved in the modulation of therapy outcome to antifolate drugs. To understand the distribution ...

mehr

17.02.2014 | Richard Tutton, Pharmacogenomics, 2014

Aim: This article investigates the number of drugs on the market with pharmacogenomics (PGx) biomarker data in their labels using two public sources – the US FDA and the PharmGKB. Methods: The article analyzes the FDA Table of Pharmacogenomic Biomarkers in Drug Labels to show the number of ...

mehr

17.02.2014 | Natascha Schweighofer; Elisabeth Lerchbaum; Olivia Trummer; Verena Schwetz; Thomas Pieber; Barbara Oberm ..., Pharmacogenomics, 2014

Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS). OCT alleles were investigated in PCOS patients to identify genetic ‘bad responders’ and ‘nonresponders’ to metformin including their possible effects on glucose metabolism without treatment. We ...

mehr